Change in FEV1 over time in COPD. [N Engl J Med. 2011] - PubMed

loading

Change in FEV1 over time in COPD. [N Engl J Med. 2011]
Change in FEV1 over time in COPD.
van Dijk WD, Schermer TR. N Engl J Med. 2011 Dec 29; 365(26):2540; author reply 2541.
Variable loss of lung function in COPD. [N Engl J Med. 2011]
Variable loss of lung function in COPD.
Burney P. N Engl J Med. 2011 Sep 29; 365(13):1246-7. Epub 2011 Sep 26.
Clinical and inflammatory factors associated with body mass index in elderly patients with chronic obstructive pulmonary disease. [Geriatr Gerontol Int. 2011]
Clinical and inflammatory factors associated with body mass index in elderly patients with chronic obstructive pulmonary disease.
Higashimoto Y, Yamagata T, Honda N, Satoh R, Sano H, Iwanaga T, Miyhara T, Muraki M, Tomita K, Tohda Y, et al. Geriatr Gerontol Int. 2011 Jan; 11(1):32-8.
Review The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression. [Am J Med. 2006]
Review The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression.
Wise RA. Am J Med. 2006 Oct; 119(10 Suppl 1):4-11.
Review Outcomes and markers in the assessment of chronic obstructive pulmonary disease. [Eur Respir J. 2006]
Review Outcomes and markers in the assessment of chronic obstructive pulmonary disease.
Jones PW, Agusti AG. Eur Respir J. 2006 Apr; 27(4):822-32.

Change in FEV1 over time in COPD.
Change in FEV1 over time in COPD.
N Engl J Med. 2011 Dec 29 ;365(26):2540; author reply 2541.

PubMed
Diabetic stem-cell "mobilopathy".
Diabetic stem-cell "mobilopathy".
N Engl J Med. 2011 Dec 29 ;365(26):2536-8.

PubMed
Proprotein convertases in health and disease.
Proprotein convertases in health and disease.
N Engl J Med. 2011 Dec 29 ;365(26):2507-18.

PubMed
A phase 3 trial of bevacizumab in ovarian cancer.
A phase 3 trial of bevacizumab in ovarian cancer.
N Engl J Med. 2011 Dec 29 ;365(26):2484-96.

PubMed
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
N Engl J Med. 2011 Dec 29 ;365(26):2473-83.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed